Sanofi
The firm is expanding its lab capabilities and leveraging its test development reputation to form partnerships early in the drug development process.
Agilent Technologies Obtains CE Mark for Expanded Use of PD-L1 CDx in NSCLC
The firm said that the expanded use for its CDx will enable European pathologists to identify patients with NSCLC who may be eligible for treatment with cemiplimab.
FDA Approves Regeneron, Sanofi's Libtayo With Agilent PD-L1 CDx in Frontline NSCLC
Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.
Sebia to Develop Dx Test for Sanofi Multiple Myeloma Treatment
The IVD test will adjust for isatuximab-induced interference in immunofixation electrophoresis tests, which can mislead clinicians in interpreting patient response.
The anticipated shortage for clinics comes at a time when more clinicians are already switching to lab-based IGRA testing, diagnostic industry executives said.